Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the best high short interest stocks with highest upside potential. On May 30, Mirum Pharmaceuticals reported positive results from its rare liver disease programs at the EASL International Liver Congress 2026. The Phase 2b VISTAS study for volixibat in primary sclerosing cholangitis/PSC demonstrated rapid, sustained, and clinically meaningful reductions in pruritus, supporting the company’s plan for an NDA submission in H2 2026.

Data from the Phase 2b AZURE-1 study of brelovitug in chronic hepatitis delta virus/HDV showed strong efficacy, with high rates of virologic response and

ALT normalization at Week 24, even in patients with advanced disease. Mirum expects topline data from its Phase 3 AZURE trials later in 2026, with potential BLA submission in 2027.

Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress

Pixabay/Public domain

Additionally, real-world evidence for the established therapy LIVMARLI (maralixibat) in progressive familial intrahepatic cholestasis/PFIC showed improved event-free survival when compared to an external control cohort. These results reinforce the long-term clinical benefits of LIVMARLI in reducing the risk of surgical biliary diversion, liver transplantation, and death in PFIC patients.

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is a biotech company that develops and commercializes novel therapies for rare & orphan diseases.

While we acknowledge the risk and potential of MIRM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MIRM and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1